Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?Christoph Röllig, Martin Bornhäuser, Edgar Jost et al.|Blood|2020Cited by 137
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaChristina Rautenberg, Jan Moritz Middeke, Friedrich Stölzel et al.|Blood Cancer Journal|2021Cited by 65
Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid LeukemiaChristoph Röllig, Martin Bornhäuser, Michael Krämer et al.|Blood|2019Cited by 18
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experienceJulius C. Enßle, Sebastian Wolf, Sebastian Scheich et al.|British Journal of Cancer|2023Cited by 8
Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patientsChristina Rautenberg, Friedrich Stölzel, Jan Moritz Middeke et al.|Blood Cancer Journal|2025Cited by 6